Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK populations [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
Analysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2-FSGS population Approximately 77% of cases in the US are predicted to involve two different NPHS2 variants (compound heterozygosity), most commonly R229Q paired with A284V. A284V is particularly prevalent in mixed-ancestry populations This modelling is supported by real world cohorts taken from clinical trial and gene panel data Finding emphasises the importance of genetic screening in adult FSGS, especially in patients resistant to immunosuppression, to establish the cause of FSGS and thereby the ideal therapy London – 29 April 2026 – Purespring Therapeutics (Purespring or the Company), a precision nephrology company advancing targeted genetic therapies to preserve kidney function in underserved populations, today announced the publication of new research demonstrating that pathogenic NPHS2 variants are a significant and under-recognised cause
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics to Report First Quarter 2026 Financial ResultsBusiness Wire
- Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (TVTX) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- Is It Time To Reassess Travere Therapeutics (TVTX) After Its Recent Price Surge [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics: Still Undervalued Post FSGS Approval [Seeking Alpha]Seeking Alpha
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 4/23/26 - Form 4
- 4/22/26 - Form 144
- 4/16/26 - Form 4
- TVTX's page on the SEC website